EXSCIENTIA SP.ADRS
Depository Receipt · US30223G1022 · EXAI · A3C4QW (XNAS)
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of EXSCIENTIA SP.ADRS
No Price
Company Profile for EXSCIENTIA SP.ADRS Depository Receipt
Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and patient selection. In addition, the company focuses on small molecule drug candidates. Its platform enables to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.
Company Data
Name EXSCIENTIA SP.ADRS
Company Exscientia plc
Symbol EXAI
Website
https://www.exscientia.ai
Primary Exchange 
Frankfurt
Frankfurt
WKN A3C4QW
ISIN US30223G1022
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO David Hallett
Market Capitalization 633 Mio
Country United Kingdom
Currency EUR
Employees 0,5 T
Address The SchrOedinger Building, OX4 4GE Oxford
IPO Date 2021-10-01
Ticker Symbols
| Name | Symbol |
|---|---|
| Frankfurt | 0RK.F |
| NASDAQ | EXAI |
More Shares
Investors who hold EXSCIENTIA SP.ADRS also have the following shares in their portfolio:
